Eukarÿs

Eukarÿs, founded in 2010 and headquartered in France, is an innovative entity in the Biotechnology industry, offering groundbreaking advancements in biologics production. Their hallmark innovation, the C3P3 RNA polymerase, is a bioengineered enzyme that promises to significantly enhance production yields — between five to seven times — in mammalian cell bioprocessing.

Central to Eukarÿs' appeal is the extensive cost-efficiency it offers without necessitating new equipment purchases, its compatibility with existing technologies, and the unaltered quality of biologics produced, including glycosylation and folding. Additionally, the enzyme's versatility allows it to facilitate the production of a wide range of pharmaceutical products, from antibodies to recombinant proteins and virus-like particles.

Notably, Eukarÿs boasts an impressive intellectual portfolio, including three patent families and multiple publications in esteemed journals like Nucleic Acids Research and Nature Scientific Reports. The company has received global recognition with prestigious awards like the Prix Galien and the Sanofi Golden Ticket, reinforcing its leadership in biotech innovation. Despite its robust scientific credentials, Eukarÿs has yet to secure its last investment round, signaling an opportunity for investors eager to engage with cutting-edge biotechnological development.